Sarah P Sherlock
Overview
Explore the profile of Sarah P Sherlock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sherlock S, McCrady A, Palmer J, Aghamolaey H, Ahlgren A, Widholm P, et al.
Muscle Nerve
. 2024 Dec;
71(3):343-352.
PMID: 39713935
Introduction/aims: Improved methodologies to monitor the progression of Duchenne muscular dystrophy (DMD) are needed, especially in the context of clinical trials. We report changes in muscle magnetic resonance imaging (MRI)...
2.
Pierce T, Ozturk A, Sherlock S, Moura Cunha G, Wang X, Li Q, et al.
Radiology
. 2024 Sep;
312(3):e233094.
PMID: 39254458
Background US shear-wave elastography (SWE) and vibration-controlled transient elastography (VCTE) enable assessment of liver stiffness, an indicator of fibrosis severity. However, limited reproducibility data restrict their use in clinical trials....
3.
Guermazi A, Roemer F, Kompel A, Diaz L, Crema M, Brown M, et al.
Osteoarthr Imaging
. 2024 Feb;
2(3-4).
PMID: 38343426
Objective: Describe the radiograph-based screening program and frequencies of ineligibility in 3 large, international, randomized, double-blind, phase 3 studies of subcutaneous tanezumab in patients with osteoarthritis (OA). Design: Standardized bilateral...
4.
Fowler K, Venkatesh S, Obuchowski N, Middleton M, Chen J, Pepin K, et al.
Radiology
. 2023 Oct;
309(1):e231092.
PMID: 37815451
Background There is a need for reliable noninvasive methods for diagnosing and monitoring nonalcoholic fatty liver disease (NAFLD). Thus, the multidisciplinary Non-invasive Biomarkers of Metabolic Liver disease (NIMBLE) consortium was...
5.
Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C, et al.
Nat Med
. 2023 Sep;
29(10):2656-2664.
PMID: 37679433
There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis (NASH), defined by the presence of NASH, high histological activity and fibrosis stage ≥2, which is associated with higher incidence...
6.
Ostergaard M, Wu J, Fallon L, Sherlock S, Wang C, Fleishaker D, et al.
Rheumatol Ther
. 2023 Jun;
10(4):1001-1020.
PMID: 37331992
Introduction: This post hoc analysis of phase 2 trial data assessed the efficacy of tofacitinib on magnetic resonance imaging (MRI) outcomes with the detailed anatomy-based Canada-Denmark (CANDEN) MRI scoring system...
7.
Sherlock S, Palmer J, Wagner K, Abdel-Hamid H, Tian C, Mah J, et al.
Sci Rep
. 2022 Nov;
12(1):18762.
PMID: 36335191
We evaluated whether whole-body dual-energy X-ray absorptiometry (DXA) measures of lean body mass can be used as biomarkers for disease progression and treatment effects in patients with Duchenne muscular dystrophy....
8.
Sherlock S, Palmer J, Wagner K, Abdel-Hamid H, Bertini E, Tian C, et al.
J Neurol
. 2022 Apr;
269(8):4421-4435.
PMID: 35396602
Duchenne muscular dystrophy (DMD) is a progressive, neuromuscular disorder caused by mutations in the DMD gene that results in a lack of functional dystrophin protein. Herein, we report the use...
9.
Sanyal A, Shankar S, Calle R, Samir A, Sirlin C, Sherlock S, et al.
Nat Med
. 2022 Feb;
28(3):430-432.
PMID: 35145308
No abstract available.
10.
Sherlock S, Zhang Y, Binks M, Marraffino S
Biomark Med
. 2021 Jun;
15(10):761-773.
PMID: 34155911
Using baseline data from a clinical trial of domagrozumab in Duchenne muscular dystrophy, we evaluated the correlation between functional measures and quantitative MRI assessments of thigh muscle. Analysis included timed...